Medindia

X

Mylan Added to NASDAQ-100 Index

Tuesday, December 15, 2009 Press Release J E 4
Advertisement


PITTSBURGH, Dec. 14 Mylan Inc. (Nasdaq: MYL) today announced that the company will be added to the NASDAQ-100 Index Dec. 21. Mylan's common shares will also be included in NASDAQ's PowerShares QQQ.

Mylan Chairman and CEO Robert J. Coury said: "We are extremely pleased to join NASDAQ's most widely followed index of leading companies. This development marks yet another significant milestone for Mylan and reflects the rapid growth and strong potential of our highly integrated and diversified global pharmaceuticals platform. Furthermore, this event underscores our reputation and performance as one of the world's most dynamic, high quality and growth-oriented companies."

The NASDAQ-100 Index consists of 100 of the largest, most innovative domestic and international non-financial securities listed on The NASDAQ Stock Market based on market capitalization. The Index reflects companies across major industry groups, including computer hardware and software, telecommunications, retail and wholesale trade, and biotechnology.

PowerShares QQQ is an Exchange Traded Fund (ETF) that seeks to replicate the NASDAQ-100 Index. It is used by investment professionals, private investors and financial advisors.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.

SOURCE Mylan Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Cancer Patients in Finland Gain Access to Advanced...
S
Manchester Announces Availability of Chenodal(TM)